Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029376 | 0.85 | TP53 (0.34) | TP53 | |
| SCHEMBL10029366 | 0.70 | TP53 (0.39) | TP53TSHRMEN1MAPTKMT2A | |
| SCHEMBL13138169 | 0.67 | TP53 (0.39) | TP53TSHRMEN1MAPTKMT2A | |
| SCHEMBL12156955 | 0.65 | TP53 (0.40) | TP53TSHRMEN1MAPTKMT2A | |
| SCHEMBL31280660 | 0.64 | TP53 (0.40) | TP53TSHRMEN1MAPTKMT2A | |
| SCHEMBL15243232 | 0.62 | TP53 (0.38) | TP53 | |
| SCHEMBL17233403 | 0.62 | TSHR (0.46) | TP53TSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL15453370 | 0.61 | MGAM (0.48) | TP53TSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL24157982 | 0.61 | TP53 (0.40) | TP53TSHRMAPTKMT2AHSD17B10 | |
| SCHEMBL4632293 | 0.59 | TP53 (0.42) | TP53TSHRMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343039-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | ROBIN JEAN-PIERRE (CH) | 2014-11-20 | — | — | US | disclosed |
| US-20140343039-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | ROBIN JEAN-PIERRE (CH) | 2014-11-20 | — | — | US | disclosed |
| US-20120022250-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | ROBIN JEAN-PIERRE (CH) | 2012-01-26 | — | — | US | disclosed |
| US-20120022250-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | ROBIN JEAN-PIERRE (CH) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022250-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | CHRM1, OPRM1, CHRM2 | TP53 4881/4885TSHR 561/4885MEN1 3409/4885 |
| US-20140343039-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | CFH, C5, CHRM1 | TP53 4881/4885TSHR 1045/4885MEN1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.